Clinical therapeutics
-
Clinical therapeutics · Oct 2011
ReviewIncidence and US costs of corticosteroid-associated adverse events: a systematic literature review.
The objective of this systematic literature review was to evaluate the incidences and risks for adverse events (AEs) associated with oral and parenteral corticosteroids. An assessment was performed to estimate the costs of such AEs. ⋯ Based on the findings from this review, systemic corticosteroids are a common cause of AEs that may be costly to payers.
-
Clinical therapeutics · Oct 2011
Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Methicillin-resistant Staphylococcus aureus (MRSA) is the primary cause of complicated bacteremia (CB) and infective endocarditis (IE). Studies have compared the costs of treatment with vancomycin to those of other agents, as well as the efficacy and tolerability of these treatments. However, a literature search found no published studies of the effects of vancomycin exposure on outcomes and hospital costs in patients with CB or IE due to MRSA. ⋯ Using the present model, cumulative vancomycin amount and duration were associated with attributable mortality and clinical failure but not with costs.